Analyst Josh Jennings from TD Cowen maintained a Buy rating on Insulet and keeping the price target at $379.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Josh Jennings has given his Buy rating due to a combination of factors, primarily focusing on Insulet’s impressive financial performance in the recent quarter. The company’s Q3 revenue and earnings per share significantly exceeded market expectations, with revenue reaching $706 million compared to the anticipated $678 million and EPS at $1.24 versus the expected $1.14.
Furthermore, Insulet has provided a strong sales growth outlook for Q4, projecting a 25-28% increase, which is notably higher than the market’s 22% target. The company has also raised its 2025 sales growth and operating margin guidance, along with an improved gross margin goal. Jennings anticipates that Insulet’s momentum will continue, driven by the expansion in the Type 2 diabetes market, further penetration in the Type 1 market, and global growth initiatives.
According to TipRanks, Jennings is a 2-star analyst with an average return of 0.6% and a 46.39% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Medtronic, TransMedics Group, and Boston Scientific.